Chlorpromazine Interactions

Co-administration may lead to torsade de pointes-type ventricular tachycardia due to QT prolongation. Avoid concomitant use.

Source: NLP:macimorelin acetate

Clorazepate dipotassium increases the inhibitory effects of chlorpromazine.

Source: NLP:clorazepate dipotassium

QT-prolonging drug with known torsades de pointes risk. Combined with fingolimod's QT prolongation and bradycardia effects, patients require overnight continuous ECG monitoring in medical facility.

Source: NLP:fingolimod

Antipsychotic that prolongs QTc interval and increases risk for Parkinsonism, NMS, and akathisia when used concomitantly with tetrabenazine.

Source: NLP:tetrabenazine

Blocks dopamine and norepinephrine reuptake, potentially inhibiting central stimulant effects of amphetamine.

Source: NLP:amphetamine sulfate

Mixing carbamazepine suspension with chlorpromazine solution results in formation of an orange rubbery precipitate. Should not be administered simultaneously.

Source: NLP:carbamazepine

Concomitant use may increase risk of water intoxication with hyponatremia; requires more frequent serum sodium monitoring.

Source: NLP:desmopressin acetate

QT-prolonging drug associated with torsades de pointes risk in bradycardia. Patients should be monitored overnight with continuous ECG in a medical facility.

Source: NLP:fingolimod hcl

CYP2D6 inhibitor that increases haloperidol plasma concentrations; monitor for increased adverse effects including QTc prolongation.

Source: NLP:haloperidol decanoate

CYP2D6 inhibitor that increases haloperidol plasma concentrations, raising risk of adverse events including QTc prolongation.

Source: NLP:haloperidol lactate

Potent CYP2D6 inhibitor may increase plasma concentration of metoprolol, decreasing cardioselectivity.

Source: NLP:metoprolol

Potent CYP2D6 inhibitor may increase metoprolol plasma concentration, decreasing cardioselectivity.

Source: NLP:metoprolol tartrate

Phenothiazine α-adrenergic blocking agent that blocks phenylephrine and is blocked by phenylephrine.

Source: NLP:phenylephrine hci

Phenothiazine α-adrenergic blocking agent that blocks phenylephrine and is blocked by phenylephrine.

Source: NLP:phenylephrine hydrochloride

Sodium sulfate, potassium sulfate, and magnesium sulfate oral solution can reduce absorption of chlorpromazine via chelation with magnesium. Administer chlorpromazine at least 2 hours before and not less than 6 hours after this product.

Source: NLP:sodium sulfate anhydrous, potassium sulfate, and magnesium sulfate

Administer at least 2 hours before and not less than 6 hours after SUPREP to avoid chelation with magnesium and reduced absorption.

Source: NLP:sodium sulfate, potassium sulfate, magnesium sulfate

Additive effect of decreased alertness and psychomotor performance observed. No pharmacokinetic interaction.

Source: NLP:zolpidem tartrate